211 related articles for article (PubMed ID: 15695296)
1. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
[TBL] [Abstract][Full Text] [Related]
2. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
[TBL] [Abstract][Full Text] [Related]
3. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
[TBL] [Abstract][Full Text] [Related]
4. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.
Schotte H; Schlüter B; Drynda S; Willeke P; Tidow N; Assmann G; Domschke W; Kekow J; Gaubitz M
Ann Rheum Dis; 2005 Apr; 64(4):575-81. PubMed ID: 15345504
[TBL] [Abstract][Full Text] [Related]
6. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.
Schotte H; Schlüter B; Willeke P; Mickholz E; Schorat MA; Domschke W; Gaubitz M
Rheumatology (Oxford); 2004 Aug; 43(8):960-4. PubMed ID: 15026584
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
[TBL] [Abstract][Full Text] [Related]
9. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.
Jamnitski A; Visman IM; Peters MJ; Dijkmans BA; Voskuyl AE; Nurmohamed MT
Ann Rheum Dis; 2010 Nov; 69(11):1929-33. PubMed ID: 20498216
[TBL] [Abstract][Full Text] [Related]
11. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
Mugnier B; Balandraud N; Darque A; Roudier C; Roudier J; Reviron D
Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
[TBL] [Abstract][Full Text] [Related]
13. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
[TBL] [Abstract][Full Text] [Related]
14. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
15. Association between a polymorphism in the lymphotoxin-a promoter region and migraine.
Lee KA; Jang SY; Sohn KM; Won HH; Kim MJ; Kim JW; Chung CS
Headache; 2007; 47(7):1056-62. PubMed ID: 17635597
[TBL] [Abstract][Full Text] [Related]
16. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
17. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
Lee YH; Ji JD; Bae SC; Song GG
J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
[TBL] [Abstract][Full Text] [Related]
18. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
[TBL] [Abstract][Full Text] [Related]
20. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
